

ASX RELEASE

13th February 2020

Professor Paul Timpson Joins Amplia's SAB

Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to announce the appointment of Professor Paul Timpson to its Scientific Advisory Board. Professor Timpson leads the Invasion and Metastasis Lab at the Garvan Institute of Medical Research and is a world leader in FAK biology. As a member of Amplia's SAB, Professor Timpson will contribute his advice and experience to the design of the Company's planned clinical studies so that they are designed with the very latest understanding of FAK biology in mind.

Dr John Lambert, Amplia's CEO and Managing Director commented that "We are delighted that Professor Timpson has agreed to join our SAB. Paul's deep understanding of FAK and the role it plays in tumour development has already provided amazing insights that we expect will directly inform the design of our planned clinical studies in cancer patients."

Professor Timpson commented that "FAK is attracting a lot of attention as a new target in cancer treatment. Our fundamental research provides the key to how best to target FAK in the clinic and our goal is to translate that research into new treatment opportunities for cancer patients. Working with companies like Amplia is how such translation occurs."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information

Dr. John Lambert
CEO and Managing Director
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

For personal use only